{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:44:17Z","timestamp":1793832257180,"version":"4.6.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.cpcardiol.2023.102194","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T23:48:04Z","timestamp":1700264884000},"page":"102194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["In patients with chronic heart failure which polypharmacy pheno-groups are associated with adverse health outcomes? (Polypharmacy pheno-groups and heart failure outcomes)"],"prefix":"10.1016","volume":"49","author":[{"given":"Mohammed Ibn-Mas'ud","family":"Danjuma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aseel Abdulrahim","family":"Sukik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Tarek","family":"Aboughalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mubarak","family":"Bidmos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousra","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Chamseddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelnaser","family":"Elzouki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oyelola","family":"Adegboye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2023.102194_bib0001","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"4 I","key":"10.1016\/j.cpcardiol.2023.102194_bib0002","article-title":"A randomized trial of \u03b2-blockade in heart failure: The Cardiac Insufficiency Bisoprolol Study (CIBIS)","volume":"90","author":"Lechat","year":"1994","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.cpcardiol.2023.102194_bib0003","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.cpcardiol.2023.102194_bib0004","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.102194_bib0005","article-title":"Polypharmacy definition and prevalence in heart failure: a systematic review","volume":"27","author":"Beezer","year":"2022","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cpcardiol.2023.102194_bib0006","doi-asserted-by":"crossref","DOI":"10.1186\/s12877-017-0621-2","article-title":"What is polypharmacy? A systematic review of definitions","author":"Masnoon","year":"2017","journal-title":"BMC Geriatr"},{"issue":"11","key":"10.1016\/j.cpcardiol.2023.102194_bib0007","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.006977","article-title":"Polypharmacy in older adults hospitalized for heart failure","volume":"13","author":"Unlu","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.102194_bib0008","unstructured":"Tamargo J., Kjeldsen K.P., Delp\u00f3n E., et al. Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Vol. 8, European heart journal. Cardiovascular pharmacotherapy. 2022."},{"issue":"6","key":"10.1016\/j.cpcardiol.2023.102194_bib0009","doi-asserted-by":"crossref","DOI":"10.1002\/pds.3764","article-title":"Register-based indicators for potentially inappropriate medication in high-cost patients with excessive polypharmacy","volume":"24","author":"Saastamoinen","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"10.1016\/j.cpcardiol.2023.102194_bib0010","article-title":"[Economic cost of polypharmacy in the elderly in primary health care]","volume":"51","author":"Santib\u00e1\u00f1ez-Beltr\u00e1n","year":"2013","journal-title":"Rev Med Inst Mex Seguro Soc"},{"issue":"9","key":"10.1016\/j.cpcardiol.2023.102194_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.jamda.2012.07.019","article-title":"Reducing cost by reducing polypharmacy: the polypharmacy outcomes project","volume":"13","author":"Kojima","year":"2012","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.cpcardiol.2023.102194_bib0012","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12981-022-00461-4","article-title":"What is polypharmacy in people living with HIV\/AIDS? A systematic review","volume":"19","author":"Danjuma","year":"2022","journal-title":"AIDS Res Ther"},{"issue":"2","key":"10.1016\/j.cpcardiol.2023.102194_bib0013","doi-asserted-by":"crossref","DOI":"10.1177\/1060028015621071","article-title":"Medication regimen complexity and polypharmacy as factors associated with all-cause mortality in older people: a population-based cohort study","volume":"50","author":"Wimmer","year":"2016","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.cpcardiol.2023.102194_bib0014","doi-asserted-by":"crossref","DOI":"10.1093\/eurpub\/cku238","article-title":"Charlson index scores from administrative data and case-note review compared favorably in a renal disease cohort","volume":"25","author":"Johnston","year":"2015","journal-title":"Eur J Public Health"},{"key":"10.1016\/j.cpcardiol.2023.102194_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2019.00048","article-title":"Comorbidity index as a predictor of mortality in pediatric patients with solid tumors","volume":"7","author":"Torres-Esp\u00edndola","year":"2019","journal-title":"Front Pediatr"},{"key":"10.1016\/j.cpcardiol.2023.102194_bib0016","doi-asserted-by":"crossref","DOI":"10.1097\/JCN.0000000000000885","article-title":"Polypharmacy and clinical outcomes in hospitalized patients with acute decompensated heart failure","author":"Ozasa","year":"2023","journal-title":"J Cardiovasc Nurs"},{"issue":"11","key":"10.1016\/j.cpcardiol.2023.102194_bib0017","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008293","article-title":"Association of hyper-polypharmacy with clinical outcomes in heart failure with preserved ejection fraction","volume":"14","author":"Minamisawa","year":"2021","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.102194_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2019.12.030","article-title":"The age adjusted Charlson comorbidity index: a significant predictor of clinical outcome in patients with heart failure","volume":"73","author":"Shuvy","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.cpcardiol.2023.102194_bib0019","article-title":"An increasing trend in the prevalence of polypharmacy in Sweden: a nationwide register-based study","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.cpcardiol.2023.102194_bib0020","doi-asserted-by":"crossref","DOI":"10.1111\/jgs.15800","article-title":"Assessing the scope and appropriateness of prescribing cascades","volume":"67","author":"McCarthy","year":"2019","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"10.1016\/j.cpcardiol.2023.102194_bib0021","article-title":"An evaluation of a potential calcium channel blocker\u2013lower-extremity edema\u2013loop diuretic prescribing cascade","volume":"58","author":"Vouri","year":"2018","journal-title":"J Am Pharm Assoc (Wash DC)"},{"key":"10.1016\/j.cpcardiol.2023.102194_bib0022","doi-asserted-by":"crossref","DOI":"10.1111\/jgs.16224","article-title":"Evaluation of the potential acetylcholinesterase inhibitor-induced rhinorrhea prescribing cascade","volume":"68","author":"Vouri","year":"2020","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.cpcardiol.2023.102194_bib0023","doi-asserted-by":"crossref","unstructured":"Schwartz J.B., Schmader K.E., Hanlon J.T., et al. Pharmacotherapy in older adults with cardiovascular disease: report from an american college of cardiology, American Geriatrics Society, and National Institute on Aging Workshop. Vol. 67, Journal of the American Geriatrics Society. 2019.","DOI":"10.1111\/jgs.15634"},{"issue":"6","key":"10.1016\/j.cpcardiol.2023.102194_bib0024","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afp165","article-title":"Charlson Comorbidity Index does not predict long-term mortality in elderly subjects with chronic heart failure","volume":"38","author":"Testa","year":"2009","journal-title":"Age Ageing"},{"issue":"658","key":"10.1016\/j.cpcardiol.2023.102194_bib0025","doi-asserted-by":"crossref","DOI":"10.3399\/bjgp17X690533","article-title":"Comorbidity and polypharmacy in chronic heart failure: a large cross-sectional study in primary care","volume":"67","author":"Baron-Franco","year":"2017","journal-title":"Br J Gen Pract"},{"issue":"5","key":"10.1016\/j.cpcardiol.2023.102194_bib0026","doi-asserted-by":"crossref","DOI":"10.1007\/s00228-010-0977-0","article-title":"Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study","volume":"67","author":"Nobili","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2023.102194_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/S1388-9842(01)00200-8","article-title":"Heart failure in frail elderly patients: diagnostic difficulties, co-morbidities, polypharmacy and treatment dilemmas","volume":"4","author":"Lien","year":"2002","journal-title":"Eur J Heart Fail"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280623006114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280623006114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:49:02Z","timestamp":1758941342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280623006114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0146280623006114"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.102194","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In patients with chronic heart failure which polypharmacy pheno-groups are associated with adverse health outcomes? (Polypharmacy pheno-groups and heart failure outcomes)","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.102194","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102194"}}